No headlines found.
CLINUVEL implements strategic reorganisation to refocus on U.S. markets
Globe Newswire (Thu, 23-Jul 12:10 AM ET)
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
Clinuvel Pharmaceuticals Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol CUVL.
As of August 17, 2026, CUVL stock price declined to $6.88 with 2,800 million shares trading.
CUVL has a market cap of $346.69 million. This is considered a Small Cap stock.
CUVL support price is $6.45 and resistance is $7.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CUVL shares will trade within this expected range on the day.
